Cargando…

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab

Purpose. To evaluate antiangiogenic effect of local use of bevacizumab (anti-VEGF antibody) in patients with corneal neovascularization. Methods. Patients were divided into two groups. All patients suffered from some form of corneal neovascularization (NV). Patients in group A received 0.2–0.5 mL of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krizova, Deli, Vokrojova, Magdalena, Liehneova, Katerina, Studeny, Pavel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981012/ https://www.ncbi.nlm.nih.gov/pubmed/24778865 http://dx.doi.org/10.1155/2014/178132

Ejemplares similares

Hybrid Technique of Lamellar Keratoplasty (DMEK-S)
por: Studeny, Pavel, et al.
Publicado: (2013)

Clinical Outcomes after Complete Intracorneal Ring Implantation and Corneal Collagen Cross-Linking in an Intrastromal Pocket in One Session for Keratoconus
por: Studeny, Pavel, et al.
Publicado: (2014)

Use of PocketMaker Microkeratome for Creation of Corneal Pocket for Foldable Keratoprosthesis KeraKlear Implantation – Case Series
por: Studeny, Pavel, et al.
Publicado: (2015)

Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
por: Sarah, Belghmaidi, et al.
Publicado: (2016)

The Application of OCTA in Assessment of Anti-VEGF Therapy for Idiopathic Choroidal Neovascularization
por: Chen, Qin, et al.
Publicado: (2016)

The Effect of Bevacizumab on Corneal Neovascularization in Rabbits
por: Kim, Wung-Jae, et al.
Publicado: (2010)

Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
por: Ahn, Ye Jin, et al.
Publicado: (2014)

The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab
por: Alkin, Zeynep, et al.
Publicado: (2013)

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
por: Britton, Anna Krystyna, et al.
Publicado: (2020)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages
por: Kwon, Junki, et al.
Publicado: (2017)

Outcomes of 23-Gauge Vitrectomy Combined with Phacoemulsification, Panretinal Photocoagulation, and Trabeculectomy without Use of Anti-VEGF Agents for Neovascular Glaucoma with Vitreous Hemorrhage
por: Yan, Hua
Publicado: (2016)

Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation
por: Starlinger, P, et al.
Publicado: (2012)

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
por: Holz, F G, et al.
Publicado: (2016)

Descemet membrane endothelial keratoplasty with a stromal rim in the treatment of posterior polymorphous corneal dystrophy
por: Studeny, Pavel, et al.
Publicado: (2012)

The Effect of Bevacizumab versus Ranibizumab in the Treatment of Corneal Neovascularization: A Preliminary Study
por: Kim, Jin-Hyoung, et al.
Publicado: (2013)

Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics
por: Su, Wenqi, et al.
Publicado: (2021)

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
por: Rusovici, Raluca, et al.
Publicado: (2011)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
por: Hashemian, Mohammad Nasser, et al.
Publicado: (2017)

Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis
por: Wu, Mingxing, et al.
Publicado: (2017)

Risk of Corneal Graft Rejection After High-risk Keratoplasty Following Fine-needle Vessel Coagulation of Corneal Neovascularization Combined With Bevacizumab: A Pilot Study
por: Hos, Deniz, et al.
Publicado: (2019)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
por: Al-Debasi, Tariq, et al.
Publicado: (2017)

Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD
por: Hatz, Katja, et al.
Publicado: (2022)

The role of Anti-VEGF agents in treatment of neovascular glaucoma
por: Palfi (Salavat), Mădălina-Casiana, et al.
Publicado: (2022)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
por: Faatz, Henrik, et al.
Publicado: (2022)

Triamcinolone Acetonide as an Adjunct to Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model
por: Mehrjardi, Hadi Z., et al.
Publicado: (2014)

Deep Sclerectomy with Nonabsorbable Implant (T-Flux) in Patients with Pseudoexfoliation Glaucoma
por: Studeny, Pavel, et al.
Publicado: (2017)

Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report
por: Iannetti, Ludovico, et al.
Publicado: (2013)

Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report
por: Donato, Mariela Grossi, et al.
Publicado: (2021)

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study
por: Jing, Jin, et al.
Publicado: (2018)

Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents
por: Garoon, Robert B., et al.
Publicado: (2016)

Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization
por: Chen, Wei-Li, et al.
Publicado: (2014)

The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model
por: Mello, Glauco Reggiani, et al.
Publicado: (2011)

LONG-TERM TREATMENT OUTCOMES AFTER BEVACIZUMAB THERAPY FOR MACULAR NEOVASCULARIZATION IN WHITE PATIENTS WITH HIGH MYOPIA
por: Ravenstijn, Monica, et al.
Publicado: (2023)

Effects of VEGF Inhibitor Conbercept on Corneal Neovascularization Following Penetrating Keratoplasty in Rabbit Model
por: Liu, Huan, et al.
Publicado: (2020)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
por: Yerramothu, Praveen
Publicado: (2018)

The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma
por: Bai, Ling, et al.
Publicado: (2022)

Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
por: Frenkel, Ronald E P, et al.
Publicado: (2016)

Individualized Corneal Patching for Treatment of Corneal Trauma Combined with Tissue Defects
por: Zhang, Ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ksf13jf3vnijk0l2058rbospp5